NASDAQ: LQDA

Liquidia (LQDA) Stock Analysis & Forecast

Nov 13 close

$57.41−0.71 (−1.2%)

Gekko Brief

AI summaryNov 9 close

Liquidia's stock moved this week on a patent settlement with United Therapeutics, which permits continued sales of YUTREPIA for pulmonary arterial hypertension in exchange for defined net payments through April 2027. Separate coverage framed Liquidia as an "affordable growth" story, citing strong revenue and earnings growth alongside a high trailing P/E but more reasonable forward valuation metrics. The company also confirmed it will report third-quarter 2026 results on 10 November, with a live webcast at 8:30 a.m. Eastern.

Shares closed at $47.87, up 7.8% on the day, but remain below both the 50-day average of $49.99 and the 200-day average of $54.45, with the 50-day below the 200-day. The GekkoIndex reads 55.1, placing it in the Neutral zone, down 2.5 points over five sessions. Gekko Fair Value stands at $51.98, putting the current price 7.9% below that level.

Liquidia reports quarterly results on 10 November, zero days away, placing earnings risk inside the typical 20-trading-day holding window; the prior release saw an 18.1% reaction on an EPS miss of $0.74 versus $0.76 expected, with 3 beats in the last 8 quarters and an average absolute reaction of 12.8%. No insider, Congress, or unusual options activity appears in the respective 90-day and 30-day windows, though one trailblazer holder is noted. Seasonally, the next 20 trading days have averaged a 11.6% gain over 5 years, rising in 5 of them. Analyst consensus across 8 firms, with 6 buy and 2 hold ratings, carries a target of $54.38.

Written by AI from the Nov 9, 2026 close and checked automatically against the figures on this page.

Liquidia price vs fair value

$57.41$53.68Nov ’25May ’26Nov ’26
Close $57.41200-day averageGekko Fair Value $53.68

Liquidia quick facts

Market cap
$5.17B
P/E ratio
—
Forward P/E
13.8
EPS, TTM
−$1.05
Revenue, TTM
$621.9M
Profit margin
-15.1%
Dividend yield
—
Beta
0.41
Volume
1.87M avg 2.91M
1-year return
+102.8%
Typical daily move
±6.3%
Typical 20-day move
±11.5%
50-day average
$48.96
200-day average
$54.71
Next earnings
Mar 4 before open
Shares outstanding
90.11M
52-week range
$22.31$93.61

Liquidia swing-trade checklist

Liquidia scores 2 supportive, 2 mixed and 1 headwind across the 5 checklist items with data.

Six things swing traders check before a 20-day hold, read from the latest data.

2 supportive2 mixed1 headwind

  • Trendmixed

    Averages disagree

    Close $57.41 sits between the 50-day ($48.96) and 200-day ($54.71) averages, or the averages disagree.

    See the chart
  • GekkoIndexmixed

    48.5, Neutral

    Reading 48.5 is in the Neutral zone.

    See the GekkoIndex
  • Fair valueheadwind

    6.9% above

    Price is 6.9% above Gekko Fair Value (more than 5% above).

    See fair value
  • Smart moneyno data

    No data

    No insider, Congress or unusual options activity in the window.

    See smart money
  • Earnings risksupportive

    Reports in 109 days

    Next report Mar 4, 2027, 109 days away — outside a typical 20-trading-day hold.

    See earnings
  • Seasonalitysupportive

    +12.3% on average

    From this point in the calendar, the next 20 trading days averaged +12.3% over 5 years, rising in 4 of them.

    See seasonality

A description of current data, not a recommendation. How this page works

Liquidia stock chart and price history

Liquidia closed at $57.41 on Nov 13, 2026, +102.8% over the past year, inside a 52-week range of $22.31 to $93.61.

Close50-day average200-day averageVolume
Liquidia share price, past year, with 50-day and 200-day moving averages and volume$20$40$80DecJan 2026FebMarAprMayJunJulAugSepOctNov57.41

Use the left and right arrow keys to read daily values.

Performance Breakdown

1 month
+65.1%
3 months
−26.1%
6 months
+0.8%
1 year
+102.8%
The full LQDA chart adds GekkoIndex, insider, options, Congress and hedge fund markers, plus TrendCandles™.Open LQDA in Gekko

Follow Liquidia through every session

Put LQDA on a Gekko watchlist and see its GekkoIndex, Gekko Fair Value and smart money signals update on the chart as they change.

Track LQDA in GekkoFree for 7 days. No credit card required.

About Liquidia

Liquidia works in biopharmaceuticals, creating, manufacturing, and bringing to market treatments meant to address important unmet needs among patients across the United States. Among its development efforts, the company is working on YUTREPIA, an inhaled dry powder formulation of treprostinil designed to treat pulmonary arterial hypertension. This program represents a central piece of its pipeline.

Alongside its work on new treatments, Liquidia also sells a generic injectable version of treprostinil to patients in the U.S. market, giving the company both a commercial product and a pipeline asset aimed at the same underlying condition.

Liquidia was established in 2004 and keeps its headquarters in Morrisville, North Carolina. Its shares trade on the NASDAQ under the ticker LQDA.

Listed
NASDAQ
Sector
Health technology
Industry
Pharmaceuticals: major
Website
liquidia.com

Liquidia GekkoIndex: the smart money zone

Liquidia’s GekkoIndex — Gekko’s 0 to 100 smart money score — reads 48.5, in the Neutral zone, down 7.8 points over five sessions.

010048.5Neutral

Down 7.8 points over five sessions.

Reading for Nov 13, 2026

What followed past readings in each zone

ZoneReadings5 days10 days20 days50 days
Buying23+10.4%+23.6%+35.9%+13.3%
Accumulation210+2.8%+2.6%+2.6%+19.3%
Neutral (current zone)413+0.8%+2.6%+6.0%+15.1%
Distribution50−1.3%+1.9%+5.2%+2.9%
Selling6Too few readings yet

Average LQDA share-price change over the trading days after each daily reading in its GekkoIndex history. Across every stock Gekko tracks, Neutral readings averaged +0.9% over 20 days. Past behaviour doesn’t guarantee future results.

Neutral zone: No clear directional signal. About the five zones →

See every daily GekkoIndex reading plotted over the LQDA price, zone by zone.Track LQDA in Gekko

Is Liquidia stock overvalued? Gekko Fair Value

Liquidia trades 6.9% above Gekko Fair Value of $53.68, so the shares are overvalued on Gekko’s estimate.

Gekko’s own estimate of what Liquidia shares are worth, recalculated every trading day.

$53.68

Gekko Fair Value, Nov 14, 2026

6.9% Overvalued

At the end of Aug 2026 the price was 30.2% below the estimate.

Gekko Fair ValueShare price, month end
$54$57Aug 2026SepOctNov 2026

How Gekko Fair Value works →

Gekko Fair Value on every chart, with the gap to price updating daily.Open LQDA in Gekko

Liquidia insider and Congress trading

No open-market insider purchases were filed for Liquidia, and no Congress trades were disclosed, in the last 90 days.

Plus buybacks, unusual options and fund positions, each dated to when it became public.

Insider buying last 90 days

No open-market insider purchases were filed for LQDA in the last 90 days.

From Form 4 filings, dated to when each was filed.

Every LQDA insider filing, plotted on the chart in Gekko.Open LQDA in Gekko

Congress trades last 90 days

No trades in LQDA were disclosed by members of Congress in the last 90 days.

From congressional disclosures, which report amounts as ranges.

Congress disclosures for LQDA, plotted on the chart in Gekko.Open LQDA in Gekko

Hedge funds and billionaires quarter ended Sep 30

0of the funds Gekko tracks hold LQDA.

0added0opened0trimmed1sold out
Which funds are on each side, name by name.Unlock in Gekko

Liquidia earnings: next date and track record

Liquidia reports on Mar 4, 2027, before the open (109 days away), and beat the EPS estimate in 3 of its last 8 reports.

3 of 8reports beat the EPS estimate
±12.8%average move across the report
5 of 8reports followed by a gain

Share-price move across each report

−5.6%Nov ’24+4.7%Mar ’25−1.7%May ’25+18.9%Aug ’25+14.6%Nov ’25+4.8%Mar ’26+33.8%May ’26−18.1%Aug ’26

Last earnings call, Aug 12, 2026 AI summary

What they said
YUTREPIA reached ~5,900 unique patient prescriptions and 5,000+ patient starts within one year of launch, with 1,100+ prescribing physicians. Net revenue approaches 30% of the inhaled treprostinil market as Q2 market grew to $607M from $573M in Q1. YUTREPIA's growth exceeded total category growth. ASCENT study showed progressive 6MWD improvements of 21.5, 31.5, and 41 meters at weeks 8, 16, and 24. Pipeline candidate L606 (twice-daily) shows strong tolerability data with lowest cough incidence reported.
Guidance
Management plans 10 clinical studies underway or starting within 12 months across YUTREPIA and L606. Business now generates sufficient cash flow to self-fund R&D investments. No specific revenue or EPS targets were provided in this excerpt.
ReportedEPSSurpriseRevenueSurpriseMove
Aug 12, 2026$0.74
est $0.76
−2.4%$171.7M
est $168.5M
+1.9%−18.1%
May 11, 2026$0.52
est $0.34
+52.9%$132.9M
est $119.4M
+11.2%+33.8%
Mar 5, 2026$0.15
est $0.08
+87.5%$92.02M
est $88.59M
+3.9%+4.8%
Nov 3, 2025−$0.04
est −$0.45
+91.1%$54.34M
est $80.72M
−32.7%+14.6%
Aug 12, 2025−$0.49
est −$0.43
−14.0%$8.84M
est $14.30M
−38.2%+18.9%
May 8, 2025−$0.45
est −$0.42
−7.1%$3.12M
est $4.16M
−25.0%−1.7%
Mar 19, 2025−$0.46
est −$0.38
−21.1%$2.92M
est $3.31M
−12.0%+4.7%
Nov 13, 2024−$0.39
est −$0.37
−4.8%$4.45M
est $4.63M
−4.0%−5.6%

“Move” is the close of the first session after the report compared with the close of the last session before it, so it reads the same whether the company reported before the open or after the close.

Liquidia stock forecast and analyst price targets

Analysts’ average 12-month price target for Liquidia is $60.75, +5.8% from the last close, from 8 firms rating the stock in the last 90 days.

$60.75consensus 12-month target, +5.8% from the last close
Low $40High $87
Buy6
Hold2
Sell0

Each firm’s latest rating in the last 90 days: 8 firms.

Latest analyst actions

DateFirmRatingTargetvs price
Nov 13H.C. WainwrightBuy, initiated$76+32.4%
Nov 11Wells FargoHold, maintained$40−30.3%
Nov 11Raymond JamesBuy, maintained$77+34.1%
Nov 11Bank of America SecuritiesHold, reiterated$54−5.9%
Nov 10JefferiesBuy, maintained$62+8.0%
+6.0%average 20-day move after past Neutral readings
+12.3%average move over the next 20 trading days in the last 5 years
±6.3%typical daily move, from the 14-day average range

Gekko doesn’t publish price predictions. These are analyst targets and historical base rates, which don’t guarantee future results.

Liquidia seasonality: the next 20 trading days

Over the next 20 trading days from Nov 14, Liquidia averaged +12.3% across the last 5 years, rising in 4 of them.

Next 20 trading days, by year

−12.8%2021+32.9%2022+12.1%2023+8.9%2024+21.9%2025

Average move and hit rate

WindowAverageYears higher
Next 5 trading days−2.7%2 of 5
Next 10 trading days+4.6%3 of 5
Next 15 trading days+9.7%4 of 5
Next 20 trading days+12.3%4 of 5
Next 30 trading days+29.7%4 of 5

For scale, LQDA’s typical 20-trading-day move in either direction is about 11.5%.

Liquidia market cap and key statistics

Liquidia’s market cap is $5.17B and revenue of $621.9M over the last twelve months.

Valuation

Market cap
$5.17B
Forward P/E
13.8
EPS, TTM
−$1.05
Gekko Fair Value
$53.68

Trading

Volume
1.87M
Avg volume, 20 days
2.91M
52-week high
$93.61
52-week low
$22.31
Shares outstanding
90.11M

Financials

Revenue, TTM
$621.9M
Profit margin
-15.1%
Return on equity
131.8%
Quarterly earnings growth, YoY
0.0%

Risk and income

Beta
0.41
Typical daily move
±6.3%
Typical 20-day move
±11.5%

Liquidia stock news this week

Coverage of Liquidia this week reads positive: 6 positive, 3 neutral and 2 negative headlines.

News sentiment positive

Liquidia peers

Liquidia’s 6 largest industry peers by market value, with today’s move, GekkoIndex zone and gap to Gekko Fair Value.

StockTodayGekkoIndex zonevs Fair Value
LLYEli Lilly+1.0%Neutral24.0% above
JNJJohnson & Johnson+0.3%Neutral4.4% above
ABBVAbbVie−0.5%Neutral23.7% above
MRKMerck+0.3%Neutral8.2% below
AZNAstraZeneca−0.2%Neutral34.6% below
PFEPfizer−0.1%Accumulation8.9% below

A peer links to its own page where one exists.

In the Buying zone today

Reporting earnings this week

Popular on Gekko

More stocks in Pharmaceuticals: major

Liquidia stock FAQ

What is Liquidia’s market cap?

Liquidia’s market cap is $5.17B at the Nov 13, 2026 close of $57.41, with 90.11M shares outstanding.

What is the Liquidia stock forecast?

The consensus analyst 12-month price target for Liquidia is $60.75, +5.8% from the last close. Of the 8 firms that rated the stock in the last 90 days, 6 rate it a buy, 2 a hold and 0 a sell. Gekko doesn’t publish price predictions of its own.

Is Liquidia stock overvalued or undervalued?

On Gekko’s estimate Liquidia is overvalued: the Nov 13, 2026 close of $57.41 is 6.9% above Gekko Fair Value of $53.68. Gekko Fair Value is recalculated every trading day, and a gap inside 5% either way counts as about fair value.

When does Liquidia report earnings next?

Liquidia is expected to report on Mar 4, 2027, before the market opens (109 days away). Analysts expect earnings of $0.39 per share on revenue of $224.7M. Liquidia beat the earnings estimate in 3 of its last 8 reports, moving 12.8% on average across the report.

What is Liquidia’s 52-week high and low?

Liquidia’s 52-week high is $93.61 and its 52-week low is $22.31; it closed at $57.41 on Nov 13, 2026, +102.8% over the past year.

Is Liquidia stock a buy right now?

Gekko describes the data; it does not make buy or sell recommendations. On the swing-trade checklist, 2 of the 5 items with data read as supportive (earnings risk and seasonality), 2 as mixed (trend and gekkoindex) and 1 as a headwind (fair value). The checklist is a description of current data, not a recommendation.

How this page works

During US trading hours the price at the top of the page is a delayed quote, refreshed every 15 minutes; everything else is rebuilt after each US market close. The GekkoIndex, Gekko Fair Value and the checklist are Gekko’s own, and the Gekko Brief is written by AI from this page’s data and checked against it before it is published. How Gekko’s data works →

See Liquidia the way Gekko members do

Every GekkoIndex reading, insider trade, options bet and Congress disclosure plotted on the chart, plus the 5,800-name screener and trade planning tools.

Join 1,475 other traders using Gekko

Start Your FREE 7 Day Trial → Every feature unlocked. No credit card required.